A carregar...

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

First-line afatinib significantly improved progression-free survival, patient-reported outcomes, and quality of life compared with chemotherapy regimens in patients with advanced epidermal-growth-factor-receptor (EGFR) mutation-positive non-small cell lung cancer, based on results of the LUX-Lung 3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Respir Dis
Main Authors: Ke, E-E, Wu, Yi-Long
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933608/
https://ncbi.nlm.nih.gov/pubmed/26929305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753465816634545
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!